JP Morgan Chase’s Surface Oncology, Inc. Common Stock SURF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,407
| Closed | -$1.22K | – | 7831 |
|
|
2023
Q2 | $1.22K | Hold |
1,407
| – | – | ﹤0.01% | 6430 |
|
|
2023
Q1 | $1K | Hold |
1,407
| – | – | ﹤0.01% | 6588 |
|
|
2022
Q4 | $1K | Sell |
1,407
-2,351
| -63% | -$2.32K | ﹤0.01% | 6479 |
|
|
2022
Q3 | $4K | Buy |
3,758
+2,423
| +181% | +$3.87K | ﹤0.01% | 6164 |
|
|
2022
Q2 | $2K | Sell |
1,335
-20,747
| -94% | -$43.1K | ﹤0.01% | 6322 |
|
|
2022
Q1 | $65K | Buy |
22,082
+4,611
| +26% | +$16.2K | ﹤0.01% | 5691 |
|
|
2021
Q4 | $84K | Buy |
17,471
+598
| +4% | +$3.86K | ﹤0.01% | 5755 |
|
|
2021
Q3 | $128K | Buy |
16,873
+1,673
| +11% | +$10.7K | ﹤0.01% | 5447 |
|
|
2021
Q2 | $113K | Buy |
15,200
+14,800
| +3,700% | +$114K | ﹤0.01% | 5501 |
|
|
2021
Q1 | $3K | Buy |
+400
| New | +$4K | ﹤0.01% | 5920 |
|
|
2020
Q4 | – | Sell |
-17,719
| Closed | -$115K | – | 6037 |
|
|
2020
Q3 | $115K | Buy |
17,719
+17,708
| +160,982% | +$107K | ﹤0.01% | 4630 |
|
|
2020
Q2 | $0 | Buy |
+11
| New | +$40 | ﹤0.01% | 5799 |
|
|
2019
Q3 | – | Sell |
-5,054
| Closed | -$14K | – | 6035 |
|
|
2019
Q2 | $14K | Buy |
5,054
+2,296
| +83% | +$9.14K | ﹤0.01% | 5512 |
|
|
2019
Q1 | $13K | Sell |
2,758
-23,164
| -89% | -$114K | ﹤0.01% | 5502 |
|
|
2018
Q4 | $110K | Buy |
25,922
+24,239
| +1,440% | +$187K | ﹤0.01% | 4816 |
|
|
2018
Q3 | $18K | Buy |
1,683
+207
| +14% | +$2.42K | ﹤0.01% | 5438 |
|
|
2018
Q2 | $24K | Buy |
+1,476
| New | +$21.4K | ﹤0.01% | 5272 |
|
JP Morgan Chase's SURF Position: Q3 2023 in Review
JP Morgan Chase sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 1,407 shares — an estimated $1.22K sold.
JP Morgan Chase first reported a position in SURF in Q2 2018 and held it in 17 quarters. The position peaked at $128K in Q3 2021. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.
- JP Morgan Chase reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- JP Morgan Chase sold 1,407 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $1.22K.
- JP Morgan Chase first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 17 quarters.
- JP Morgan Chase's Surface Oncology, Inc. Common Stock position peaked at $128K in Q3 2021.
- 0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.
Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.